Lamotrigine (All indications) - Medication and Pregnancy KB

Lamotrigine (All indications) updated on 04-22-2025

Spina bifida

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S19314 R81790	Kim (Lamotrigine) (Indications NOS), 2026	Spina bifida	1st trimester	population based cohort retrospective	unexposed (general population or NOS)	Adjustment: Yes	0.57 [0.07;4.85]	1/718 5,503/2,489,078	5,504	718		ref
S10035 R36148	Blotière (Lamotrigine) (Mixed indications), 2019	Spina bifida	1st trimester	retrospective cohort (claims database)	unexposed (general population or NOS)	Adjustment: No	1.02 [0.14;7.23] ^C	1/2,997 616/1,875,733	617	2,997		ref
S8965 R30362	Veiby (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2014	Spina bifida	throughout pregnancy	population based cohort retrospective	unexposed, sick	Adjustment: No Controls: epilepsy indication	0.65 [0.03;12.54] ^C	0/833 3/3,773	3	833		ref
S8905 R30090	Charlton (Lamotrigine), 2011	Spina bifida	1st trimester	retrospective cohort (claims database)	unexposed, sick	Adjustment: No	1.85 [0.09;38.71] ^C	0/98 2/902	2	98		ref
					Total	4 studies	0.86 [0.26;2.84]		6,126	4,646
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Lamotrigine) (Indications NOS; 2: Lamotrigine) (Mixed indications; 3: Lamotrigine) (Controls unexposed, sick) (Mixed indications; 4: Lamotrigine;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Sub-groups analysis using all included studies

excluded